Hematology

Teclistamab showed promising clinical activity and a tolerable safety profile in patients with relapsed/refractory multiple myeloma.

The FDA has approved axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

There are specific treatment options patients may qualify for depending on the cytogenetic or molecular abnormality detected.

Investigators recommended avoiding risk factors such as smoking and switching to a transdermal administration route for testosterone.

The FDA has approved melphalan flufenamide (Pepaxto; melflufen) for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.

Study findings illustrate the need for better communication between health care providers and patients experiencing concerns during the pandemic.

Study findings suggest that enhanced cleaning and disinfecting policies are effective at reducing the spread of COVID-19.

A more sensitive test capable of detecting heart function issues early in cancer treatment may be beneficial in preventing heart failure.

The research will have implications for clinicians when prescribing blood-thinning medications after Fontan surgery, a complex congenital heart disease operation redirecting blood flow from the lower body to the lungs.

Presentation provides an overview of recent FDA approvals for therapies utilized in patients with various cancer types.

Health care providers should monitor blood pressure starting in early adolescence, especially for individuals at high cardiovascular risk, such as Black populations.

Data show that 1 in 5 men and women worldwide develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease, according to the study.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic the next steps for his CAEL-101 findings, a treatment for patients living with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic his recent CAEL-101 findings, and how it can help shape treatment for patients living with amyloid light chain amyloidosis.

The BTD designations for asciminib were based on the phase 3, multicenter, open-label, randomized ASCEMBL trial and a phase I trial that included patients with Ph+ CML, some of them harboring the T315I mutation.

Of 192 study participants who received Breyanzi, 73% achieved a response, including 54% who had minimal or no detectable lymphoma remaining following treatment and 19% who achieved a partial response.

The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about what CAEL-101 is, how it works, and how it is used to treat patients with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis.

Since its introduction to the US market in 2003, questions have risen as to the safety, long-term consequences, and risk of cardiovascular detriments that e-cigarettes pose to users.

Rather than having an intrinsically lower risk of severe COVID-19, the patients in the study may have adhered more strictly to social distancing guidelines compared to the general population.

Patients with AML that has gone into remission following initial chemotherapy were found to remain in remission longer and have improved OS if they took a pill form of azacitidine as a maintenance treatment.

The study authors found marked improvements in rates of hazardous prescribing over the 12-month study period and the success of the intervention was sustained at the end.

Stroke is not among the covered diagnoses for cardiac rehab, despite many similar cardiovascular risk factors, according to the study.

Numerous therapeutic options are available for acute myeloid leukemia, but more research is needed to determine how best to use them.